The discovery of AZD9164, a novel muscarinic M3 antagonist

The discovery of AZD9164, a novel muscarinic M3 antagonist The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD Cyclohexylmethylpiperidinyltriphenylpropioamide:  A Selective Muscarinic M₃ Antagonist Discriminating against the Other Receptor Subtypes Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists Discovery ofN-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M₁Receptor Agonist with Unprecedented Selectivity and Procognitive Potential Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan -muscarinic antagonists with a novel chemotype Discovery of 3-(5-Chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a Novel Highly Selective α4β2 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders